Axona is a new medical food product for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease (AD).
Axona has been shown in randomized, placebo controlled clinical trials to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD. It will be marketed as an adjunctive therapy to currently approved AD drugs.
Axona will be administered under physician supervision and dispensed by prescription, in accordance with applicable FDA regulations. Axona will be distributed nationwide and will be available through retail pharmacies by prescription. Accera is currently seeking partners to commercialize Axona outside the US.
Steve Orndorff, founder and CEO of Accera, said: “The recent financing will allow us to launch Axona, a new and novel approach to managing Alzheimer’s disease. We have developed an experienced commercial manufacturing, sales and marketing team that has a history of successful commercialization of numerous central nervous system drugs. This team is prepared for the challenge of launching the first AD product in recent years with a new mechanism of action.”